Table 1.
Clinical and laboratory data of patients classified according to coronary artery lesion extension.
| Variables | Without (35) | Extension of coronary lesion | Major (23) | p | |
|---|---|---|---|---|---|
| Low (38) | Intermediate (41) | ||||
| Age, years | 53 ± 10a,b,c | 60 ± 10 | 61 ± 9 | 63 ± 7 | <0.001 |
| Sex male, % | 45.7 (16) | 65.8 (25) | 56.2 (23) | 43.5 (10) | 0.242 |
| BMI, kg/m2 | 29.2 ± 5.0 | 25.7 ± 6.1 | 27.1 ± 4.7 | 27.7 ± 4.6 | 0.043 |
| Obesity, % | 37.1 (13) | 10.8 (4) | 19.6 (8) | 14.3 (3) | 0.155 |
| Dyslipidaemia, % | 82.9 (29) | 84.2 (32) | 90.0 (36) | 78.3 (18) | 0.640 |
| Diabetes, % | 22.9 (8) | 21.1 (8) | 31.7 (13) | 39.1 (9) | 0.380 |
| Hypertension, % | 74.3 (26) | 84.2 (32) | 85.4 (35) | 87.0 (20) | 0.520 |
| Diastolic pressure, mmHg | 80 ± 10 | 84 ± 18 | 88 ± 18 | 82 ± 20 | 0.115 |
| Systolic pressure, mmHg | 134 ± 23d | 141 ± 21 | 153 ± 37d | 141 ± 22 | 0.198 |
| Physical activity, % | 31.4 (11) | 44.7 (16) | 39.0 (16) | 31.8 (7) | 0.627 |
| Alcohol intake, % | 32.4 (11) | 39.5 (15) | 17.1 (7) | 34.8 (8) | 0.157 |
| Smoking, % | 14.3 (5) | 26.3 (11) | 26.8 (6) | 26.1 (6) | 0.539 |
| Family history of CAD, % | 45.7 (16) | 44.7 (17) | 51.2 (21) | 42.5 (10) | 0.918 |
| Glucose, mg/dl | 104.6 ± 34.7 | 101.4 ± 29.0 | 134.0 ± 80.0 | 119.8 ± 47.7 | 0.070 |
| Total cholesterol, mg/dL | 174.6 ± 36.6 | 179.3 ± 55.7 | 183.7 ± 52.2 | 183.0 ± 54.1 | 0.871 |
| HDL cholesterol, mg/dL | 38.0 ± 12.8 | 35.6 ± 11.3 | 34.9 ± 10.1 | 40.3 ± 12.1 | 0.262 |
| LDL cholesterol, mg/dL | 101.4 ± 33.9 | 105.4 ± 47.5 | 113.1 ± 43.6 | 113.3 ± 44.1 | 0.594 |
| Triglycerides, mg/dL | 176.3 ± 99.4 | 191.9 ± 121.7 | 182.6 ± 130.2 | 146.8 ± 76.3 | 0.496 |
| AST, U/L | 36.6 ± 20.1 | 31.6 ± 13.9 | 31.0 ± 15.8 | 31.4 ± 18.4 | 0.541 |
| ALT, U/L | 31.2 ± 20.3 | 34.1 ± 15.4 | 27.9 ± 20.2 | 26.6 ± 16.8 | 0.048 |
| Urea, mg/dL | 35.8 ± 10.2 | 37.8 ± 9.4 | 38.3 ± 10.9 | 43.0 ± 17.2 | 0.147 |
| Creatinine, mg/dL | 0.87 ± 0.25 | 0.96 ± 0.25 | 0.90 ± 0.21 | 0.87 ± 0.33 | 0.476 |
| Uric acid, mg/dL | 5.0 ± 1.7 | 4.9 ± 1.6 | 4.4 ± 1.6 | 4.7 ± 1.3 | 0.397 |
| Antihypertensive, % | 62.9 (22) | 78.9 (30) | 65.9 (27) | 73.9 (17) | 0.423 |
| Anticoagulants, % | 25.7 (9) | 31.6 (12) | 41.5 (17) | 30.4 (7) | 0.517 |
| Antidiabetics, % | 20.0 (7) | 13.2 (7) | 17.1 (7) | 34.8 (8) | 0.211 |
| Statins, % | 14.3 (5) | 26.3 (10) | 29.3 (12) | 60.9 (14)d,e,f | 0.002 |
Data are shown as the mean ± standard deviation or the percentage for categorical variables (number of patients). Parametric analysis was performed by ANOVA. For non-parametric testing, the Kruskal–Wallis test was used. Categorical variables were compared by Chi-square test. BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; AST, aspartate aminotransferase; ALT, alanine transaminase. ‘Without’, Friesinger index 0; ‘Low’, Friesinger index 1–5; ‘Intermediate’, Friesinger index 6–10; ‘Major’, Friesinger index 11–15.
ap = 0.023, without vs low extension of coronary lesion by post-hoc Tukey test.
bp = 0.002, without vs intermediate extension of coronary lesion by post-hoc Tukey test.
cp = 0.01, without vs major extension of coronary lesion by post-hoc Tukey test.
dp < 0.010, without vs major extension of coronary lesion by Chi-square test.
ep = 0.007, low vs major extension of coronary lesion by Chi-square test.
fp < 0.013, intermediate vs major extension of coronary lesion by Chi-square test.